US 12,440,470 B2
Liquid tasimelteon formulations and methods of use thereof
Deepak Phadke, Olathe, KS (US); and Mihael Polymeropoulos, Potomac, MD (US)
Assigned to Vanda Pharmaceuticals Inc., Washington, DC (US)
Filed by Vanda Pharmaceuticals Inc., Washington, DC (US)
Filed on Jul. 31, 2023, as Appl. No. 18/362,194.
Application 17/216,427 is a division of application No. 17/119,953, filed on Dec. 11, 2020, granted, now 11,202,770, issued on Dec. 21, 2021.
Application 18/362,194 is a continuation of application No. 17/216,427, filed on Mar. 29, 2021, granted, now 11,759,446.
Claims priority of provisional application 62/947,774, filed on Dec. 13, 2019.
Claims priority of provisional application 62/972,902, filed on Feb. 11, 2020.
Claims priority of provisional application 63/119,488, filed on Nov. 30, 2020.
Prior Publication US 2023/0372285 A1, Nov. 23, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/343 (2006.01); A61K 9/08 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/26 (2006.01); A61K 47/38 (2006.01)
CPC A61K 31/343 (2013.01) [A61K 9/08 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/26 (2013.01); A61K 47/38 (2013.01)] 3 Claims
 
1. A homogeneous aqueous suspension of tasimelteon, comprising:
1 to 6 mg/mL tasimelteon;
a suspending agent;
1 to 15 mg/mL HPMC;
200 to 400 mg/mL mannitol;
50 to 200 mg/mL sorbitol;
an antioxidant;
a preservative;
a high intensity sweetener; and
a flavoring agent.